DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2003/0228333 A1 Fecht Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2003/0228333 A1 Fecht Et Al US 20030228333A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0228333 A1 Fecht et al. (43) Pub. Date: Dec. 11, 2003 (54) SUBSTITUTED HYDROCARBYL Publication Classification FUNCTIONAL SILOXANES FOR HOUSEHOLD, HEALTH, AND PERSONAL (51) Int. Cl." .............................. A61K 7/16; A61K 7/42; CARE APPLICATIONS A61K 7/135; A61K 31/695; A61K 7/06 (76) Inventors: Cassandre Michelle Fecht, Sanford, (52) U.S. Cl. .............................. 424/401; 424/59; 514/63; MI (US); Deborah Lynn Meyers, 424/62; 424/49 Midland, MI (US); Heidi Marie Van Dort, Sanford, MI (US); Isabelle Van Reeth, Incourt (BE) (57) ABSTRACT Correspondence Address: DOW CORNING CORPORATION CO1232 Cosmetic, household, and medical compositions containing 2200 W. SALZBURG ROAD certain substituted hydrocarbyl functional siloxane fluids or P.O. BOX 994 certain Substituted hydrocarbyl functional Siloxane resins MIDLAND, MI 48686-0994 (US) provide good aesthetic, Solvency, and Stability performance, and are useful as delivery vehicles for personal, health, and (21) Appl. No.: 10/157,639 household care ingredients Such as pigments, antiperspirant Salts, drugs, Sunscreens, alpha-hydroxy fatty acids, and (22) Filed: May 28, 2002 Vitamins. US 2003/0228333 A1 Dec. 11, 2003 SUBSTITUTED HYDROCARBYL FUNCTIONAL SUMMARY OF THE INVENTION SILOXANES FOR HOUSEHOLD, HEALTH, AND PERSONAL CARE APPLICATIONS 0008. This invention relates to a composition which is a guar gum free and hydroxyStearic acid derivative free mix FIELD OF THE INVENTION ture of (i) a substituted hydrocarbyl functional siloxane fluid, or a Substituted hydrocarbyl functional Siloxane resin; 0001. In the household, health and personal care areas, and (ii) a cosmetic ingredient, a household care ingredient, the need exists for Silicone raw materials that contain both or a health care ingredient, and (iii) an optional cosmetic hydrophilic and hydrophobic functionality. To date, this active, a household care active, or a health care active Such need has been addressed with polyoxyalkylene and Silanol as an antiacne agent, anticaries agent, antidandruff agent, functional Silicone materials. These structures have a num antifungal agent, antimicrobial agent, antioxidant, antiper ber of limitations including unpleasant aesthetics and acid/ Spirant agent, cosmetic biocide, deodorant agent, external base instability, respectively. analgesic, oral care agent, oral care drug, oxidizing agent, 0002 The present invention relates to cosmetic, house reducing agent, skin bleaching agent, skin protectant, Sun hold and healthcare compositions containing Substituted Screen agent, UV light absorbing agent, pigments, moistur hydrocarbyl functional Siloxane Structures for improved izers, Vitamins, enzymes, optical brighteners, fabric Soften performance and/or Stability. In an alternate embodiment, ing agents, or Surfactants. certain Substituted hydrocarbyl functional organosiloxane 0009. These and other features of the invention will resins can be included in the compositions. become apparent from a consideration of the detailed description. BACKGROUND OF THE INVENTION 0.003 Polar silicone compounds have found use in a DETAILED DESCRIPTION OF THE number of different types of products ranging from cosmet INVENTION ics to car polish formulations. Most of these products have 0010. The present invention is based on the unexpected been formulated as aerosol or pump Sprays, liquids, roll-on discovery that the inclusion of a substituted hydrocarbyl liquids, creams, emulsions, gels, gel-Solids, or Solid Stick functional Siloxane, in particular, results in personal care, formulations, and Sometimes comprise an additional active medical and household care compositions with novel prop material, e.g. Vitamins, erties. For example, compositions containing Such siloxanes 0004 alpha-hydroxy-acids, Zirconium salts or combina impart the following characteristics when compared to Simi tions thereof, incorporated into a Suitable carrier. lar formulations without Such siloxanes: (a) remain stable at relatively high and low pH; (b) compatibilize both polar and 0005 These products are designed to provide a variety of non-polar Solvents; (c) offer high lubricity; (d) mitigate skin benefits, for example, moisturize dry skin, mask Surface discomfort or irritation; (e) impart a Smooth, Soft, moist imperfections, and allow effective perspiration and odor texture, (f) evenly disperse active agents and pigments, (g) control while being cosmetically acceptable during and after detackify formulation components, (h) moisturize the skin; application onto the axillary region or other areas of the skin. (i) enhance the durability of formulation components; () Polar Silicone compounds used in these applications include enhance Surface Shine; (k) impart the Sensory performance polydiorganosiloxane-polyoxyalkylene copolymers and Sil of higher molecular weight Structures; (1) protect the hair anol functional Substituted Siloxane Structures. cuticle; (m) aid curl retention, (n) Sustain fragrance release; 0006 The preparation of siloxane-oxyalkylene copoly (o) impart Softness to Solid Substrates; (p) increase water mers by hydrosilylation of an organohydrogensiloxane absorbency of fabrics; (q) mask Surface imperfections; (r) (SiH) and an olefinically substituted polyoxyalkylene is well reduce whitening of antiperspirant salts, (s) modify formu known and reported in the literature. The hydrosilylation lation rheology, (t) improve particulate active Suspension; reaction is typically performed in a low molecular weight (u) improve ease of ironing, (v) enable the Suspension and Volatile hydrocarbon Solvent Such as benzene, toluene, delivery of polar materials in non-polar Solvents; and (w) Xylene, or isopropanol to aid in handling the reactants, to enhance emulsion Stability. moderate an exothermic reaction or to promote the Solubility 0011 AS used herein, the terms personal care composi of the reactants. The CPA catalyzed reaction of Si-H tion, health care composition, and household care compo polymers with allyl ethers was disclosed in U.S. Pat. No. Sition are intended to mean typical materials commercially 2,823,218 (Feb. 11, 1958). Typically, although not exclu available as products or raw materials in consumer markets Sively, the Smallest oxyalkylene Substitutents disclosed in containing active and inactive ingredients. patents are EO and PO. This is because of the ready availability of the Starting materials and Synthetic ease of 0012. In the preferred embodiment, the compositions of making allyloxypolyethers with that minimum Substitution. the present invention comprise at least one Substituted hydrocarbyl functional Siloxane. These siloxanes generally 0007) While U.S. Pat. No. 5,486,566 (Jan. 23, 1996) and U.S. Pat. No. 6,060,044 (May 9, 2000) describe silicone have a formula Selected from the group consisting of: ethers containing only a single oxyalkylene unit in any RSiO(RR'SiO),SiR, chain, the compositions containing Such Silicone ethers must Rs. SiO(RSiO) (RR'SiO)SiRs, necessarily include guar gum or an hydroxyStearic acid RRSiO(RSiO)SiRR', derivative for effectiveness, whereas compositions accord ing to this invention possess the above described benefits RRSiO(RR'SiO)SiRR', without requiring the use of guar gum and hydroxyStearic R" RSiO(RSiO),(RR'SiO),SiRR', acid derivatives. R"RSiO(RSiO)SiRs, US 2003/0228333 A1 Dec. 11, 2003 RRSiO(RR'SiO)SiR, a nitro group. In addition, the hydrogen atom can be Sub R"RSiO(RSiO) (RR'SiO)SiR, and cyclic silox Stituted with a group containing a Sulfur atom to form anes of the formula -SOH. -(MeSiO) (MeR'SiO)-. 0022. The Substituted hydrocarbyl functional siloxanes of 0013 In these formulas, R is an alkyl, cycloalkyl, alk the present invention can be made by Standard processes enyl, aralkyl, or an aryl group containing 1-20 carbon atoms, Such as the hydrosilylation of organohydrogensiloxanes and R" is a group having one of the formulas (i)-(iv): olefinically substituted polyoxyalkylenes. The hydrosilyla tion reaction is typically performed in a low molecular -(CH2)(OCH2CH)OR (i) weight volatile hydrocarbon Solvent Such as benzene, tolu -(CH),(OCHCHCH)OR (ii) ene, Xylene, or isopropanol to aid in handling the reactants, -(CH),IOCHCH(CHCH.) IOR’ (iii) to moderate an exothermic reaction or to promote the Solubility of the reactants. Such processes are described, for -(R)OR (iv) example, in the 218 patent noted above, which is incorpo 0014) whereina is 3-11; b is 1-50; R is selected from the group consisting of hydrogen, an alkyl group, an aryl group, rated herein by reference. an arylalkyl group and an acyl group, X is 1-500, y is 1-40, 0023 These silicone compounds are useful in a number of different products, including hair care products Such as Z is 1-40, m is 1-6, n is 1-6, and the Sum of m+n is 3-12. hairsprays, Shampoos, mousses, Styling gels and lotions, 0.015 For the sake of simplicity in nomenclature in the cream rinses/conditioners, hair tonics, hair dyes and colo Examples, these Substituted hydrocarbyl siloxanes are rants, permanent waves and bleaches. Also included are skin referred to as the CARBINOLFLUID. In preferred embodi care products Such as cleansers, moisturizers, conditioners, ments of the invention, and in the Examples, R is the methyl lipsticks, eye makeup, foundations, fingernail polish, Suntan group, R' is -(CH2),(OCH2CH)OR, products, antiperSpirant/deodorant products and depilato ries. Also included are household products Such as waxes, 0016 R is hydrogen, a is 3, X
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Commission Decision of 8 February 2010 Concerning The
    L 36/36 EN Official Journal of the European Union 9.2.2010 COMMISSION DECISION of 8 February 2010 concerning the non-inclusion of certain substances in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (notified under document C(2010) 751) (Text with EEA relevance) (2010/72/EU) THE EUROPEAN COMMISSION, concerned should therefore not be included in Annex I, IA or IB to Directive 98/8/EC. Having regard to the Treaty on the Functioning of the European Union, (6) In the interest of legal certainty, biocidal products Having regard to Directive 98/8/EC of the European Parliament containing active substances for the product-types and of the Council of 16 February 1998 concerning the placing indicated in the Annex to this Decision should no of biocidal products on the market ( 1), and in particular the longer be placed on the market, with effect from a second subparagraph of Article 16(2) thereof, specific date. Whereas: (7) The measures provided for in this Decision are in accordance with the opinion of the Standing (1) Commission Regulation (EC) No 1451/2007 of Committee on Biocidal Products, 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive HAS ADOPTED THIS DECISION: 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the Article 1 market ( 2) establishes a list of active substances to be assessed, with a view to their possible inclusion in The substances indicated in the Annex to this Decision shall not Annex I, IA or IB to Directive 98/8/EC.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,253,711 Mondshine (45) Date of Patent: Oct
    USOO525371 1A United States Patent (19) 11 Patent Number: 5,253,711 Mondshine (45) Date of Patent: Oct. 19, 1993 54) PROCESS FOR DECOMPOSING 2,268,215 12/1941 Kerr ...................................... 127/33 POLYSACCHARDES IN ALKALINE 3,167,510 /1965 Alter ..... sa as A8 a X8 a P. 252/8.551 3,655,644 4/1972 Durand ........................... 106/21 X AQUEOUS SYSTEMS 3,935,187 1/1976 Speakman ........................... 536/102 75 Inventor: Thomas C. Mondshine, Houston, 4,202,795 5/1980 Burnham et al. ............... 166/308 X Tex. 4,552,668 11/1985 Brown et al. ................... 166/300X Lachenal et al. ..................... 162/25 Assignee: Texas United Chemical Corp., 4,787,959 11/1988 (73) Primary Examiner-George A. Suchfield Houston, Tex. Attorney, Agent, or Firm-Roy F. House 21 Appl. No.: 844,167 57 ABSTRACT 22 Filed: Mar. 2, 1992 Alkaline earth metal or transition metal peroxides are (51) int. Cli.............................................. E21B 43/26 used as a delayed breaker in alkaline aqueous fluids 52) U.S. C. .................................... 166/300; 166/308; containing a water soluble hydrophilic polysaccharide 252/8.551; 252/326 polymer hydrated therein. The peroxide is activated by (58) Field of Search ............................... 166/300, 308; increasing the temperature of the fluid. The invention is 252/8.551, 326,358; 536/41, 80, 88 particularly useful for the delayed break of hydraulic 56) References Cited fracturing fluids containing hydroxypropyl guar poly c. U.S. PATENT DOCUMENTS i,953,398 4/1934 Eskew ................................... 536/41 10 Claims, No Drawings 5,253,711 1. 2 G. W. Hawkins, and H. D. Brannon, Feb.
    [Show full text]
  • Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr
    _ US005120325A Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr. [45] Date of Patent: Jun. 9, 1992 [54] COLOR-MATCHED STERILE ADHESIVE 4,561,435 12/1985 McKnight et al. ............... .. 604/304 BANDAGES CONTAINING MELANINLIKE 4,699,792 10/1987 Nick et a1. 1 . .. 604/307 PIGMENT COMPOSITION 4.710,191 12/1987 Kwiatek et a1. 604/304 4,728,323 3/1988 Matson .............. .. ‘604/304 [75] Inventor: James E. Dow, Jr., Hackensack, NJ. 4,745,916 5/1988 Seber ..... .. 128/155 , 4,895,727 l/l990 Allen 424/642 [731 Asslgnw Fleshtones Products (30-11119, 4,990,144 2/1991 Blott .................................. .. 604/304 Hackensack, NJ. Primary Examiner-David Isabella 1211 Appl- N04 713,827 Assistant Examiner—Dinh X. Nguyen [22] Filed: Jam 12, 1991 Attorney, Agent, or Firm-Carl W1 Battle [51] 11.1.0.5 ..................... .. A61F 13/00; A61F 13/02 [57] ABSTRACT [52] U.S. Cl. .................................. .. 604/304; 604/307; A sterile bandage suitable for external application to a 602/41; 602/42; 602/58 wound or injury of the human skin comprising a back [58] Field of Search .............. .. 604/304, 307; 128/156; ing layer, a non-toxic pigmented composition coated 424/447, 448 onto or embedded into the top side of said backing [56] References Cited layer, wherein said pigmented composition comprises one or more pigments having a melanin likeness in ap U.S. PATENT DOCUMENTS pearance so as to substantially match the appearance of said human skin. 3,987,202 10/1976 Okun ................................... .. 424/70 4,161,176 7/1979 Harris, U et a1.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Fluoride Gels Help Prevent and Control Dental Caries | ACFF
    Fluoride Gels Full Summary Description: Fluoride-containing gels have been used as topical applications for over 50 years in order to help prevent or control dental caries. The gels were historically intended as a professional measure but nowadays are also used for self-application at home. In both cases, a prescription from a dentist is required. There are three principal gel formulations available , i) 2% sodium fluoride with neutral or basic pH, ii) 1.23% acidulated phosphate fluoride (APF) with pH around 3.5, and iii) 1.25% amine fluoride gel (0.25% of the amine fluorides olaflur and dectaflur, and the rest in the form of 1% sodium fluoride). The gels are flavored and colored but contain no abrasive cleaning agents or preservatives. The clinical characteristics high fluoride concentration and a long contact time with the teeth allow the dental professional to place the fluoride gel allowing for long interval between fluoride gel applications. Use and application: The treatment is preceded by professional tooth cleaning, rinsing and air drying in all patients with sub-optimal oral hygiene. The gels are applied with the aid of plastic or disposable Styrofoam trays of adequate size for the patient. The tray should cover the entire dentition and reach beyond the neck of the teeth and contact the alveolar mucosa. In rare cases, individual custom fit trays can be considered. A ribbon of gel is placed in the tray which is seated over the entire dental arch. It is recommended that the trays are kept in place for 4 minutes and the patient is advised not to eat, drink or rinse for 30 minutes following the application.
    [Show full text]
  • Chemical List
    1 EXHIBIT 1 2 CHEMICAL CLASSIFICATION LIST 3 4 1. Pyrophoric Chemicals 5 1.1. Aluminum alkyls: R3Al, R2AlCl, RAlCl2 6 Examples: Et3Al, Et2AlCl, EtAlCl2, Me3Al, Diethylethoxyaluminium 7 1.2. Grignard Reagents: RMgX (R=alkyl, aryl, vinyl X=halogen) 8 1.3. Lithium Reagents: RLi (R = alkyls, aryls, vinyls) 9 Examples: Butyllithium, Isobutyllithium, sec-Butyllithium, tert-Butyllithium, 10 Ethyllithium, Isopropyllithium, Methyllithium, (Trimethylsilyl)methyllithium, 11 Phenyllithium, 2-Thienyllithium, Vinyllithium, Lithium acetylide ethylenediamine 12 complex, Lithium (trimethylsilyl)acetylide, Lithium phenylacetylide 13 1.4. Zinc Alkyl Reagents: RZnX, R2Zn 14 Examples: Et2Zn 15 1.5. Metal carbonyls: Lithium carbonyl, Nickel tetracarbonyl, Dicobalt octacarbonyl 16 1.6. Metal powders (finely divided): Bismuth, Calcium, Cobalt, Hafnium, Iron, 17 Magnesium, Titanium, Uranium, Zinc, Zirconium 18 1.7. Low Valent Metals: Titanium dichloride 19 1.8. Metal hydrides: Potassium Hydride, Sodium hydride, Lithium Aluminum Hydride, 20 Diethylaluminium hydride, Diisobutylaluminum hydride 21 1.9. Nonmetal hydrides: Arsine, Boranes, Diethylarsine, diethylphosphine, Germane, 22 Phosphine, phenylphosphine, Silane, Methanetellurol (CH3TeH) 23 1.10. Non-metal alkyls: R3B, R3P, R3As; Tributylphosphine, Dichloro(methyl)silane 24 1.11. Used hydrogenation catalysts: Raney nickel, Palladium, Platinum 25 1.12. Activated Copper fuel cell catalysts, e.g. Cu/ZnO/Al2O3 26 1.13. Finely Divided Sulfides: Iron Sulfides (FeS, FeS2, Fe3S4), and Potassium Sulfide 27 (K2S) 28 REFERRAL
    [Show full text]
  • Precautions Interactions Pharmacokinetics
    Sodium Silicofluoride 2091 7. McDonagh MS, et al. Systematic review of water fluoridation. BMJ 2000; r r Crest; Sensodyne iso-active; Soluvite; Tri-A-Vite F; Tri-Vi-Flor; 321: 855-9. P.. �P.?. c:Jii?,n,�............................. ............................................. Tri-Vi-Floro; Trivitamin Fluoride Drops; Vi-Daylin/F; Venez. : 8. Rock WP, Sabieha AM The relationship between reported toothpaste . (details are given in Volume B) Sensodyne. usage in infancy and fluorosis of permanent incisors. Br Dent J 1997; 183: ProprietaryPreparations 165-70. Single-ingredientPrepara6ons, Arg. : Aquafresh Ultimate White; 9. Steiner M, et al. Effect of 1000 ppm relative to 250 ppm fluoride Elgydium Junior; Elgydium ProtecTion Caries; Fluordent; PharmacopoeialPrepara6ons toothpaste: a meta-analysis. Am J Dent 2004; 17: 85-8. BP 2014: Sodium Fluoride Mouthwash; Sodium Fluoride Oral Fluorogel; Fluoroplat; Naf Buches; Opalescence; Austral.: Flur­ Drops; Sodium Fluoride Oral Solution; Sodium Fluoride Tablets; etst; NeutraFluor; Austria: Duraphat; Fluodontt; Sensodyne 36: Gum disease. In the Davangere district of India, the fluo­ USP Minerals Capsules; Minerals Tablets; Oil- and Water­ Proschmelz; Zymafluor; Belg.: Fluodontyl; Fluor; Z-Fluor; soluble Vitamins with Minerals Capsules; Oil- and Water-soluble ride concentration in the drinking water ranges from 1.5 Braz.: Fluotrat; Canad. : Fluocalt; Fluor-A-Day; Nafrinset; Oro­ Vitamins with Minerals Oral Solution; Oil- and Water-soluble to 3 ppm; there is virtually no dental care. In a study of NaFt;
    [Show full text]
  • Of 8 August 2014 Amending Annexes III, V and VI to Regulation (EC) No 1223/2009 of the European Parliament and the Council on Cosmetic Products
    9.8.2014 EN Official Journal of the European Union L 238/3 COMMISSION REGULATION (EU) No 866/2014 of 8 August 2014 amending Annexes III, V and VI to Regulation (EC) No 1223/2009 of the European Parliament and the Council on cosmetic products (Text with EEA relevance) THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (1), and in particular Article 31(2) thereof, Whereas: (1) The substances identified by the denominations alkyl (C12-22) trimethyl ammonium bromide and chloride are regu­ lated as preservatives under entry 44 of Annex V to Regulation (EC) No 1223/2009 with a maximum concentra­ tion of 0,1 %. (2) The Scientific Committee on Consumer Products (‘SCCP’), subsequently replaced by the Scientific Committee on Consumer Safety (‘SCCS’) pursuant to Commission Decision 2008/721/EC (2), evaluated the safety of alkyl (C16, C18, C22) trimethylammonium chloride (cetrimonium chloride, steartrimonium chloride and behentrimonium chloride) for other uses than as preservatives in 2005, 2007 and 2009. (3) The SCCS concluded in its opinion of 8 December 2009 (3) that, apart from the fact that quaternary ammonium derivative formulations have the potential to be skin irritants, especially when combinations of the concerned compounds are used, the use of cetrimonium chloride, steartrimonium chloride and behentrimonium chloride does not pose a risk to the health of the consumer in concentrations below certain limits, which are explicitly set out in the SCCS opinion.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]